Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
NCT05751681·Not applicable·INTERVENTIONAL

Dydrogesterone-Primed Ovarian Stimulation Protocol Versus Gonadotropin Releasing Hormone Antagonist Protocol in ICSI

CetrorelixOtherUnknown

Status

Unknown

Phase

Not applicable

Enrollment

79

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

GnRH antagonist protocol is currently a good strategy for controlled ovarian stimulation in women with PCOS undergoing IVF/ICSI cycles. Finding a protocol that can be a better alternative will help in improving the success rate of IVF/ICSI cycles

Full detailed description

Progesterone has potent restraint on hypothalamus-pituitary-ovarian axis. It acts on unidentified hypothalamic pulse oscillator neurons. In turn, it acts on gonadotropins releasing hormone (GnRH) secreting neurons leading to inhibition of GnRH secretion. This results in inhibition of both luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from anterior pituitary. The effect of progesterone appears to decrease GnRH pulse frequency which results in slowing down LH pulse frequency and reducing LH plasma concentrations

Interventions

Treatment arms and agents.

OTHER

progestin primed ovarian stimulation protocol

progestin primed ovarian stimulation protocol

DRUG

dydrogesterone (Duphaston, Abbott)

20 mg oral dose of dydrogesterone (Duphaston, Abbott)

DRUG

Cetrotide

0.25 mg of Cetrotide (gonadotropin releasing hormone (GnRH) antagonist)

Timeline

From registration to results.

  1. First posted

    Mar 2, 2023

  2. Study start

    Feb 20, 2023

  3. Primary completion

    Apr 20, 2024

  4. Study completion

    Mar 20, 2025

  5. Results posted

    Not reported

  6. Registry updated

    Mar 2, 2023

Outcomes

What the study measures.

Primary outcomes

Efficacy (Number of MII oocytes retrieved)

Time frame · 3 months

this outcome means to measure Percentage (number) of MII oocytes retrieved During our study

Efficacy (Maturation index)

Time frame · 3 months

Maturation index will be calculated: Rate of metaphase-II oocytes (MII) to total oocytes

Secondary outcomes

Not reported in the indexed record.

Eligibility

Who can take part.

Minimum age
20 Years
Maximum age
40 Years
Sex
FEMALE
Healthy volunteers
No

Inclusion Criteria: 1. All patients should be candidates for ICSI. 2. Age between 20-40 years. 3. Body mass index 18-35 kg/m2. 4. Diagnosis of PCOS according to modified Rotterdam's criteria Exclusion Criteria: * 1\) Any patient with contraindication to IVF treatment or pregnancy 2) Women with history of intra-uterine abnormality. 3) Severe endometriosis (grade 3 or 4) 4) Clinically significant systemic disease or other endocrinopathy.

Study locations

1 registered sites.

Egypt. Showing up to 24 locations stored in the fast local snapshot.

Zagazig University

Zagazig, Egypt

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

ClinicalTrials.gov ↗Search PubMed ↗Search FDA ↗Search EMA ↗

Related trials

More studies on Cetrorelix.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.

TrialsCetrorelix trial dashboard →DatabaseCetrorelix database entry →ResearchCetrorelix research guide →